STUDY | **Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma: updated analysis from the phase 3 IKEMA trial**

Population: N = 302

Primary endpoint: Progression-free survival

Eligibility: Not refractory to anti-CD38 therapy; R/R MM with 1–3 prior lines of therapy; no previous carfilzomib; no primary refractory MM; ECOG ≤2

TRIAL DESIGN

Randomization in a 3:2 ratio

Treatment arm, n = 179 (**Isatuximab** + Carfilzomib + Dexamethasone)

Control arm, n = 123 (Carfilzomib + Dexamethasone)

Isatuximab

10 mg/kg

Cycle 1 days

1 8 15 22

Subsequent cycle days

1 15

Carfilzomib

Cycle 1 days

1 2 — 20 mg/m²

8 9 15 16 — 56 mg/m²

Subsequent cycle days

1 2 8 9 15 16

56 mg/m²

Dexamethasone

20 mg

All cycles days

1 2 8 9

15 16 22 23

28-day cycles; to PD or unacceptable toxicity

EFFICACY

Median progression-free survival

NR *vs* 19.15 months

HR, 0.53; 99% CI, 0.32–0.89;
one-sided p = 0.0007

2-year progression-free survival rate





SAFETY

Patients with TAEs leading to treatment discontinuation



Most common TEAEs (any grade):



Grade ≥3 hematologic AEs:



Moreau P, et al. *Lancet*. 2021;397(10292):2361-2371.
DOI: 10.1016/S0140-6736(21)00592-4. **NCT03275285**

MultipleMyelomaHub